{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:00:44Z","timestamp":1780520444012,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K12HL141954"],"award-info":[{"award-number":["K12HL141954"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K12HL141954"],"award-info":[{"award-number":["K12HL141954"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK042667"],"award-info":[{"award-number":["R01DK042667"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80633-6","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:23:31Z","timestamp":1732710211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glycosphingolipids and their impact on platelet activity in a murine model of fabry disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-0475","authenticated-orcid":false,"given":"Adam J.","family":"Kanack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Prodoehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ishihara-Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-0590","authenticated-orcid":false,"given":"Nancy M.","family":"Dahms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"80633_CR1","doi-asserted-by":"crossref","unstructured":"Anderson, W. A CASE OF \u201cANGEIO\u2010KERATOMA.\u201d *. British Journal of Dermatology 10 (1898).","DOI":"10.1111\/j.1365-2133.1898.tb16317.x"},{"key":"80633_CR2","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1073\/pnas.85.11.3903","volume":"85","author":"DF Bishop","year":"1988","unstructured":"Bishop, D. F., Kornreich, R. & Desnick, R. J. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3\u2019 untranslated region. Proc Natl Acad Sci U S A 85, 3903\u20133907. https:\/\/doi.org\/10.1073\/pnas.85.11.3903 (1988).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"80633_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady, R. O. et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276, 1163\u20131167. https:\/\/doi.org\/10.1056\/NEJM196705252762101 (1967).","journal-title":"N Engl J Med"},{"key":"80633_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry, J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Archiv f\u00fcr Dermatologie und Syphilis 43, 187\u2013200. https:\/\/doi.org\/10.1007\/BF01986897 (1898).","journal-title":"Archiv f\u00fcr Dermatologie und Syphilis"},{"key":"80633_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/2271173b0","volume":"227","author":"JA Kint","year":"1970","unstructured":"Kint, J. A. The enzyme defect in Fabry\u2019s disease. Nature 227, 1173. https:\/\/doi.org\/10.1038\/2271173b0 (1970).","journal-title":"Nature"},{"key":"80633_CR6","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts, J. M. et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105, 2812\u20132817. https:\/\/doi.org\/10.1073\/pnas.0712309105 (2008).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"80633_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton, B. K. et al. Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience. J Pediatr 190, 130\u2013135. https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.048 (2017).","journal-title":"J Pediatr"},{"key":"80633_CR8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","volume":"176","author":"C Colon","year":"2017","unstructured":"Colon, C. et al. Newborn screening for Fabry disease in the north-west of Spain. Eur J Pediatr 176, 1075\u20131081. https:\/\/doi.org\/10.1007\/s00431-017-2950-8 (2017).","journal-title":"Eur J Pediatr"},{"key":"80633_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","volume":"57","author":"DP Germain","year":"2020","unstructured":"Germain, D. P. et al. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. J Med Genet 57, 542\u2013551. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106467 (2020).","journal-title":"J Med Genet"},{"key":"80633_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist, M. et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet 60, 391\u2013396. https:\/\/doi.org\/10.1136\/jmg-2022-108523 (2023).","journal-title":"J Med Genet"},{"key":"80633_CR11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu, W. L. et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30, 1397\u20131405. https:\/\/doi.org\/10.1002\/humu.21074 (2009).","journal-title":"Hum Mutat"},{"key":"80633_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 281, 249\u2013254. https:\/\/doi.org\/10.1001\/jama.281.3.249 (1999).","journal-title":"JAMA"},{"key":"80633_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38, 769\u2013775. https:\/\/doi.org\/10.1136\/jmg.38.11.769 (2001).","journal-title":"J Med Genet"},{"key":"80633_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/archopht.1979.01020010327008","volume":"97","author":"NA Sher","year":"1979","unstructured":"Sher, N. A., Letson, R. D. & Desnick, R. J. The ocular manifestations in Fabry\u2019s disease. Arch Ophthalmol 97, 671\u2013676. https:\/\/doi.org\/10.1001\/archopht.1979.01020010327008 (1979).","journal-title":"Arch Ophthalmol"},{"key":"80633_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/archopht.1965.00970040762005","volume":"74","author":"GL Spaeth","year":"1965","unstructured":"Spaeth, G. L. & Frost, P. Fabry\u2019s disease. Its ocular manifestations. Arch Ophthalmol 74, 760\u2013769. https:\/\/doi.org\/10.1001\/archopht.1965.00970040762005 (1965).","journal-title":"Arch Ophthalmol"},{"key":"80633_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N Uceyler","year":"2014","unstructured":"Uceyler, N., Ganendiran, S., Kramer, D. & Sommer, C. Characterization of pain in fabry disease. Clin J Pain 30, 915\u2013920. https:\/\/doi.org\/10.1097\/AJP.0000000000000041 (2014).","journal-title":"Clin J Pain"},{"key":"80633_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00401-005-0026-8","volume":"111","author":"C Navarro","year":"2006","unstructured":"Navarro, C. et al. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathol 111, 178\u2013185. https:\/\/doi.org\/10.1007\/s00401-005-0026-8 (2006).","journal-title":"Acta Neuropathol"},{"key":"80633_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu, C. H. et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157, 331\u2013337. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08002.x (2007).","journal-title":"Br J Dermatol"},{"key":"80633_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/adc.47.251.26","volume":"47","author":"DM Flynn","year":"1972","unstructured":"Flynn, D. M., Lake, B. D., Boothby, C. B. & Young, E. P. Gut lesions in Fabry\u2019s disease without a rash. Arch Dis Child 47, 26\u201333. https:\/\/doi.org\/10.1136\/adc.47.251.26 (1972).","journal-title":"Arch Dis Child"},{"key":"80633_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries, M. et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162, 767\u2013772. https:\/\/doi.org\/10.1007\/s00431-003-1299-3 (2003).","journal-title":"Eur J Pediatr"},{"issue":"Suppl 2","key":"80633_CR21","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","volume":"13","author":"M Branton","year":"2002","unstructured":"Branton, M., Schiffmann, R. & Kopp, J. B. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2), S139-143 (2002).","journal-title":"J Am Soc Nephrol"},{"key":"80633_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000488121","volume":"43","author":"M Del Pino","year":"2018","unstructured":"Del Pino, M. et al. Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney Blood Press Res 43, 406\u2013421. https:\/\/doi.org\/10.1159\/000488121 (2018).","journal-title":"Kidney Blood Press Res"},{"key":"80633_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/hrt.2004.054015","volume":"92","author":"PM Elliott","year":"2006","unstructured":"Elliott, P. M. et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92, 357\u2013360. https:\/\/doi.org\/10.1136\/hrt.2004.054015 (2006).","journal-title":"Heart"},{"key":"80633_CR24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","volume":"15","author":"B Tomberli","year":"2013","unstructured":"Tomberli, B. et al. Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail 15, 1363\u20131373. https:\/\/doi.org\/10.1093\/eurjhf\/hft104 (2013).","journal-title":"Eur J Heart Fail"},{"key":"80633_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","volume":"46","author":"E Kolodny","year":"2015","unstructured":"Kolodny, E. et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 46, 302\u2013313. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006283 (2015).","journal-title":"Stroke"},{"key":"80633_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta, A. et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 46, 548\u2013552. https:\/\/doi.org\/10.1136\/jmg.2008.065904 (2009).","journal-title":"J Med Genet"},{"key":"80633_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin, E. R. et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med 19, 430\u2013438. https:\/\/doi.org\/10.1038\/gim.2016.122 (2017).","journal-title":"Genet Med"},{"key":"80633_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 375, 545\u2013555. https:\/\/doi.org\/10.1056\/NEJMoa1510198 (2016).","journal-title":"N Engl J Med"},{"key":"80633_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54, 288\u2013296. https:\/\/doi.org\/10.1136\/jmedgenet-2016-104178 (2017).","journal-title":"J Med Genet"},{"key":"80633_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00395-012-0311-3","volume":"108","author":"JM Lorenzen","year":"2013","unstructured":"Lorenzen, J. M. et al. Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. Basic Res Cardiol 108, 311. https:\/\/doi.org\/10.1007\/s00395-012-0311-3 (2013).","journal-title":"Basic Res Cardiol"},{"key":"80633_CR31","doi-asserted-by":"publisher","first-page":"e009098","DOI":"10.1161\/JAHA.118.009098","volume":"7","author":"H Yogasundaram","year":"2018","unstructured":"Yogasundaram, H. et al. Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 7, e009098. https:\/\/doi.org\/10.1161\/JAHA.118.009098 (2018).","journal-title":"J Am Heart Assoc"},{"key":"80633_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1096\/fj.201800771R","volume":"33","author":"JJ Miller","year":"2019","unstructured":"Miller, J. J. et al. alpha-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. FASEB J 33, 418\u2013429. https:\/\/doi.org\/10.1096\/fj.201800771R (2019).","journal-title":"FASEB J"},{"key":"80633_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99171","author":"JJ Miller","year":"2018","unstructured":"Miller, J. J. et al. Neuropathic pain in a Fabry disease rat model. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.99171 (2018).","journal-title":"JCI Insight"},{"key":"80633_CR34","doi-asserted-by":"publisher","first-page":"9392","DOI":"10.1038\/s41598-019-45837-1","volume":"9","author":"JJ Miller","year":"2019","unstructured":"Miller, J. J. et al. Rats deficient in alpha-galactosidase A develop ocular manifestations of Fabry disease. Sci Rep 9, 9392. https:\/\/doi.org\/10.1038\/s41598-019-45837-1 (2019).","journal-title":"Sci Rep"},{"key":"80633_CR35","doi-asserted-by":"publisher","first-page":"e21818","DOI":"10.1096\/fj.202001727RR","volume":"35","author":"AJ Kanack","year":"2021","unstructured":"Kanack, A. J., Aoki, K., Tiemeyer, M. & Dahms, N. M. Platelet and myeloid cell phenotypes in a rat model of Fabry disease. FASEB J 35, e21818. https:\/\/doi.org\/10.1096\/fj.202001727RR (2021).","journal-title":"FASEB J"},{"key":"80633_CR36","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2015-01-569129","volume":"126","author":"R Grozovsky","year":"2015","unstructured":"Grozovsky, R., Giannini, S., Falet, H. & Hoffmeister, K. M. Regulating billions of blood platelets: glycans and beyond. Blood 126, 1877\u20131884. https:\/\/doi.org\/10.1182\/blood-2015-01-569129 (2015).","journal-title":"Blood"},{"key":"80633_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327\u2013334. https:\/\/doi.org\/10.1038\/nature12984 (2014).","journal-title":"Nature"},{"key":"80633_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102507","author":"Y Raza","year":"2021","unstructured":"Raza, Y., Salman, H. & Luberto, C. Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment. Cells https:\/\/doi.org\/10.3390\/cells10102507 (2021).","journal-title":"Cells"},{"key":"80633_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116145","author":"S Groux-Degroote","year":"2021","unstructured":"Groux-Degroote, S. & Delannoy, P. Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms22116145 (2021).","journal-title":"Int J Mol Sci"},{"key":"80633_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/glycob\/cws061","volume":"22","author":"Z Wang","year":"2012","unstructured":"Wang, Z. et al. High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients. Glycobiology 22, 930\u2013938. https:\/\/doi.org\/10.1093\/glycob\/cws061 (2012).","journal-title":"Glycobiology"},{"key":"80633_CR41","doi-asserted-by":"publisher","unstructured":"Rosa Neto, N. S., Bento, J. C. B., Caparbo, V. F. & Pereira, R. M. R. Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden. Clinics (Sao Paulo) 76:e2643 (2021). https:\/\/doi.org\/10.6061\/clinics\/2021\/e2643","DOI":"10.6061\/clinics\/2021\/e2643"},{"key":"80633_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini, G. B. et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 1822, 226\u2013232. https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.001 (2012).","journal-title":"Biochim Biophys Acta"},{"key":"80633_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ymgme.2019.05.009","volume":"127","author":"N Uceyler","year":"2019","unstructured":"Uceyler, N. et al. Tumor necrosis factor-alpha links heat and inflammation with Fabry pain. Mol Genet Metab 127, 200\u2013206. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.009 (2019).","journal-title":"Mol Genet Metab"},{"key":"80633_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132, 52\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2006.11.041 (2007).","journal-title":"Gastroenterology"},{"key":"80633_CR45","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst, D. E. et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30, 2563\u20132571 (2003).","journal-title":"J Rheumatol"},{"key":"80633_CR46","doi-asserted-by":"publisher","unstructured":"Hanauer, S. B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 130, 323\u2013333; quiz 591 (2006). https:\/\/doi.org\/10.1053\/j.gastro.2005.11.030","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"80633_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48, 35\u201345. https:\/\/doi.org\/10.1002\/art.10697 (2003).","journal-title":"Arthritis Rheum"},{"key":"80633_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach, S. M. et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802, 741\u2013748. https:\/\/doi.org\/10.1016\/j.bbadis.2010.05.003 (2010).","journal-title":"Biochim Biophys Acta"},{"key":"80633_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1515\/CCLM.2010.048","volume":"48","author":"R Kruger","year":"2010","unstructured":"Kruger, R. et al. Determination of globotriaosylceramide in plasma and urine by mass spectrometry. Clin Chem Lab Med 48, 189\u2013198. https:\/\/doi.org\/10.1515\/CCLM.2010.048 (2010).","journal-title":"Clin Chem Lab Med"},{"key":"80633_CR50","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1073\/pnas.92.11.5087","volume":"92","author":"T Mutoh","year":"1995","unstructured":"Mutoh, T., Tokuda, A., Miyadai, T., Hamaguchi, M. & Fujiki, N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci U S A 92, 5087\u20135091. https:\/\/doi.org\/10.1073\/pnas.92.11.5087 (1995).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"80633_CR51","doi-asserted-by":"publisher","first-page":"9044","DOI":"10.1073\/pnas.1105666108","volume":"108","author":"U Coskun","year":"2011","unstructured":"Coskun, U., Grzybek, M., Drechsel, D. & Simons, K. Regulation of human EGF receptor by lipids. Proc Natl Acad Sci U S A 108, 9044\u20139048. https:\/\/doi.org\/10.1073\/pnas.1105666108 (2011).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"80633_CR52","doi-asserted-by":"publisher","first-page":"109142","DOI":"10.1016\/j.celrep.2021.109142","volume":"35","author":"K Okubo","year":"2021","unstructured":"Okubo, K. et al. Inhibitory affinity modulation of FcgammaRIIA ligand binding by glycosphingolipids by inside-out signaling. Cell Rep 35, 109142. https:\/\/doi.org\/10.1016\/j.celrep.2021.109142 (2021).","journal-title":"Cell Rep"},{"key":"80633_CR53","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/cdd.2008.115","volume":"15","author":"K Chakrabandhu","year":"2008","unstructured":"Chakrabandhu, K. et al. The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ 15, 1824\u20131837. https:\/\/doi.org\/10.1038\/cdd.2008.115 (2008).","journal-title":"Cell Death Differ"},{"key":"80633_CR54","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 18, e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410 (2020).","journal-title":"PLoS Biol"},{"key":"80633_CR55","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat Methods"},{"key":"80633_CR56","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.thromres.2005.04.026","volume":"117","author":"S Nylander","year":"2006","unstructured":"Nylander, S., Mattsson, C. & Lindahl, T. L. Characterisation of species differences in the platelet ADP and thrombin response. Thromb Res 117, 543\u2013549. https:\/\/doi.org\/10.1016\/j.thromres.2005.04.026 (2006).","journal-title":"Thromb Res"},{"key":"80633_CR57","doi-asserted-by":"publisher","DOI":"10.3791\/61068","author":"XD Manz","year":"2020","unstructured":"Manz, X. D. et al. In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time. J Vis Exp https:\/\/doi.org\/10.3791\/61068 (2020).","journal-title":"J Vis Exp"},{"key":"80633_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0003-2697(92)90048-c","volume":"203","author":"KR Anumula","year":"1992","unstructured":"Anumula, K. R. & Taylor, P. B. A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates. Anal Biochem 203, 101\u2013108. https:\/\/doi.org\/10.1016\/0003-2697(92)90048-c (1992).","journal-title":"Anal Biochem"},{"key":"80633_CR59","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1021\/acs.jproteome.6b00132","volume":"15","author":"N Mehta","year":"2016","unstructured":"Mehta, N. et al. Mass Spectrometric Quantification of N-Linked Glycans by Reference to Exogenous Standards. J Proteome Res 15, 2969\u20132980. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00132 (2016).","journal-title":"J Proteome Res"},{"key":"80633_CR60","doi-asserted-by":"publisher","first-page":"9127","DOI":"10.1074\/jbc.M606711200","volume":"282","author":"K Aoki","year":"2007","unstructured":"Aoki, K. et al. Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo. J Biol Chem 282, 9127\u20139142. https:\/\/doi.org\/10.1074\/jbc.M606711200 (2007).","journal-title":"J Biol Chem"},{"key":"80633_CR61","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2008-04-149641","volume":"112","author":"L Nimrichter","year":"2008","unstructured":"Nimrichter, L. et al. E-selectin receptors on human leukocytes. Blood 112, 3744\u20133752. https:\/\/doi.org\/10.1182\/blood-2008-04-149641 (2008).","journal-title":"Blood"},{"key":"80633_CR62","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jasms.2005.01.013","volume":"16","author":"Z Vukelic","year":"2005","unstructured":"Vukelic, Z. et al. Screening and sequencing of complex sialylated and sulfated glycosphingolipid mixtures by negative ion electrospray Fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom 16, 571\u2013580. https:\/\/doi.org\/10.1016\/j.jasms.2005.01.013 (2005).","journal-title":"J Am Soc Mass Spectrom"},{"key":"80633_CR63","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/hmg\/ddt434","volume":"23","author":"L Boccuto","year":"2014","unstructured":"Boccuto, L. et al. A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum Mol Genet 23, 418\u2013433. https:\/\/doi.org\/10.1093\/hmg\/ddt434 (2014).","journal-title":"Hum Mol Genet"},{"key":"80633_CR64","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/glycob\/cwz045","volume":"29","author":"S Neelamegham","year":"2019","unstructured":"Neelamegham, S. et al. Updates to the Symbol Nomenclature for Glycans guidelines. Glycobiology 29, 620\u2013624. https:\/\/doi.org\/10.1093\/glycob\/cwz045 (2019).","journal-title":"Glycobiology"},{"key":"80633_CR65","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1074\/mcp.E113.027904","volume":"12","author":"L Wells","year":"2013","unstructured":"Wells, L., Hart, G. W., Athens Guidelines for the Publication of Glycomics, D. Glycomics: building upon proteomics to advance glycosciences. Mol Cell Proteomics 12, 833\u2013835. https:\/\/doi.org\/10.1074\/mcp.E113.027904 (2013).","journal-title":"Mol Cell Proteomics"},{"key":"80633_CR66","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/glycob\/cwu018","volume":"24","author":"WS York","year":"2014","unstructured":"York, W. S. et al. MIRAGE: the minimum information required for a glycomics experiment. Glycobiology 24, 402\u2013406. https:\/\/doi.org\/10.1093\/glycob\/cwu018 (2014).","journal-title":"Glycobiology"},{"key":"80633_CR67","doi-asserted-by":"publisher","first-page":"D1523","DOI":"10.1093\/nar\/gkaa1012","volume":"49","author":"Y Watanabe","year":"2021","unstructured":"Watanabe, Y., Aoki-Kinoshita, K. F., Ishihama, Y. & Okuda, S. GlycoPOST realizes FAIR principles for glycomics mass spectrometry data. Nucleic Acids Res 49, D1523\u2013D1528. https:\/\/doi.org\/10.1093\/nar\/gkaa1012 (2021).","journal-title":"Nucleic Acids Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80633-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80633-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80633-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:10:53Z","timestamp":1732713053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80633-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80633"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80633-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"NMD is a member of the scientific advisory board of M6P Therapeutics. AJK, EP, MI-A, and KA declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29488"}}